Interactive Brokers IBKR Soars 4.93% on Q2 Earnings Surge

Generated by AI AgentAinvest Pre-Market Radar
Friday, Jul 18, 2025 4:05 am ET1min read
IBKR--
Aime RobotAime Summary

- Interactive Brokers Group's stock surged 4.93% in pre-market trading on July 18, driven by strong Q2 financial performance.

- The company reported a 20.3% revenue increase to $1.48 billion and adjusted EPS of $0.51, exceeding forecasts.

- Analysts set a $62.78 average price target, with a "Outperform" consensus, indicating strong confidence.

- Commission revenue rose 27%, and 250,000 new accounts were added, boosting valuation metrics.

Interactive Brokers Group's stock surged 4.93% in pre-market trading on July 18, 2025, driven by strong Q2 financial performance.

Interactive Brokers reported a 20.3% increase in revenue for the second quarter, reaching $1.48 billion. This significant growth was driven by higher trading volumes and increased net interest income. The company's adjusted earnings per share of $0.51 exceeded market forecasts of $0.47, contributing to the positive market sentiment.

Analysts have set an average one-year price target of $62.78 for Interactive Brokers, with estimates ranging from $50.00 to $69.00. This suggests a potential upside of 5.63% from the current trading price. The consensus recommendation from brokerage firms is an "Outperform" status, indicating strong confidence in the company's future performance.

Interactive Brokers also reported a 27% increase in commission revenue and a 9% rise in net interest income. The company added 250,000 new accounts during the quarter, reflecting robust account growth and innovation. The strong financial performance has led to a higher valuation, with shares now trading at a price-to-earnings ratio of 31, up from 5 three months ago.

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet